State Street
CSTL icon

State Street’s Castle Biosciences CSTL Stock Holding History

State Street’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6M Buy
822,079
+53,000
+7% +$1.18M ﹤0.01% 2369
2026
Q1 		$18.9M Buy
769,079
+32,625
+4% +$1.07M ﹤0.01% 2268
2025
Q4 		$28.6M Buy
736,454
+12,374
+2% +$399K ﹤0.01% 2054
2025
Q3 		$16.5M Buy
724,080
+16,393
+2% +$333K ﹤0.01% 2344
2025
Q2 		$14.5M Sell
707,687
-7,341
-1% -$136K ﹤0.01% 2364
2025
Q1 		$14.3M Buy
715,028
+4,816
+0.7% +$119K ﹤0.01% 2309
2024
Q4 		$18.9M Buy
710,212
+30,211
+4% +$920K ﹤0.01% 2260
2024
Q3 		$19.4M Buy
680,001
+60,924
+10% +$1.55M ﹤0.01% 2220
2024
Q2 		$13.5M Buy
619,077
+13,278
+2% +$296K ﹤0.01% 2386
2024
Q1 		$13.4M Buy
605,799
+25,881
+4% +$563K ﹤0.01% 2404
2023
Q4 		$12.5M Buy
579,918
+14,754
+3% +$260K ﹤0.01% 2467
2023
Q3 		$9.55M Buy
565,164
+29,836
+6% +$522K ﹤0.01% 2625
2023
Q2 		$7.34M Buy
535,328
+12,800
+2% +$259K ﹤0.01% 2803
2023
Q1 		$11.9M Buy
522,528
+18,075
+4% +$442K ﹤0.01% 2556
2022
Q4 		$11.9M Buy
504,453
+6,528
+1% +$151K ﹤0.01% 2594
2022
Q3 		$13M Sell
497,925
-6,599
-1% -$185K ﹤0.01% 2539
2022
Q2 		$11.1M Buy
504,524
+45,819
+10% +$1.06M ﹤0.01% 2660
2022
Q1 		$20.6M Buy
458,705
+2,666
+0.6% +$110K ﹤0.01% 2377
2021
Q4 		$19.6M Buy
456,039
+21,202
+5% +$1.11M ﹤0.01% 2494
2021
Q3 		$28.9M Buy
434,837
+3,939
+0.9% +$277K ﹤0.01% 2207
2021
Q2 		$31.6M Buy
430,898
+125,419
+41% +$8.28M ﹤0.01% 2189
2021
Q1 		$20.9M Buy
305,479
+44,056
+17% +$3.31M ﹤0.01% 2348
2020
Q4 		$17.6M Buy
261,423
+53,303
+26% +$2.89M ﹤0.01% 2316
2020
Q3 		$10.7M Buy
208,120
+21,262
+11% +$946K ﹤0.01% 2406
2020
Q2 		$7.04M Buy
186,858
+36,879
+25% +$1.26M ﹤0.01% 2588
2020
Q1 		$4.47M Buy
149,979
+98,866
+193% +$2.98M ﹤0.01% 2678
2019
Q4 		$1.76M Buy
51,113
+15,091
+42% +$369K ﹤0.01% 3287
2019
Q3 		$652K Buy
+36,022
New +$799K ﹤0.01% 3467

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

State Street's CSTL Position: Q2 2026 in Review

State Street increased its Castle Biosciences (CSTL) stake by 6.9% in Q2 2026, buying an estimated $1.18M and bringing the position to 822,079 shares worth $19.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2369.

State Street first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $31.6M in Q2 2021. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • State Street held 822,079 shares of Castle Biosciences worth $19.6M as of Q2 2026.
  • State Street bought 53,000 Castle Biosciences shares in Q2 2026, an estimated $1.18M.
  • Castle Biosciences made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2369 holding.
  • State Street first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • State Street's Castle Biosciences position peaked at $31.6M in Q2 2021.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.